BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27410488)

  • 1. Hepcidin independent iron recycling in a mouse model of β-thalassaemia intermedia.
    Frazer DM; Wilkins SJ; Mirciov CS; Dunn LA; Anderson GJ
    Br J Haematol; 2016 Oct; 175(2):308-317. PubMed ID: 27410488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
    Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
    J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.
    Frazer DM; Wilkins SJ; Darshan D; Badrick AC; McLaren GD; Anderson GJ
    Br J Haematol; 2012 Jun; 157(5):615-26. PubMed ID: 22449175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
    Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
    Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous iron increases hemoglobin in beta-thalassemic mice.
    Ginzburg YZ; Rybicki AC; Suzuka SM; Hall CB; Breuer W; Cabantchik ZI; Bouhassira EE; Fabry ME; Nagel RL
    Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
    Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW
    Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269
    [No Abstract]   [Full Text] [Related]  

  • 8. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
    Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
    Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Putative Erythroid Regulators of Hepcidin in Mouse Models of Anemia.
    Mirciov CS; Wilkins SJ; Dunn LA; Anderson GJ; Frazer DM
    PLoS One; 2017; 12(1):e0171054. PubMed ID: 28135344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary supplementation with ipriflavone decreases hepatic iron stores in wild type mice.
    Patchen B; Koppe T; Cheng A; Seo YA; Wessling-Resnick M; Fraenkel PG
    Blood Cells Mol Dis; 2016 Sep; 60():36-43. PubMed ID: 27519943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
    Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
    Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
    Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
    J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.
    Gutschow P; Schmidt PJ; Han H; Ostland V; Bartnikas TB; Pettiglio MA; Herrera C; Butler JS; Nemeth E; Ganz T; Fleming MD; Westerman M
    Haematologica; 2015 Feb; 100(2):167-77. PubMed ID: 25425686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.
    Ganz T; Nemeth E
    Semin Nephrol; 2016 Mar; 36(2):87-93. PubMed ID: 27236128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
    Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
    Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
    Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
    Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
    Camaschella C; Nai A
    Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
    Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
    Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
    Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.